Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Conditions
Brief summary
To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.
Interventions
Sponsors
Pharmaceutical Research Network
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension * the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM * visual acuity should be 20/200 or better in each eye
Exclusion criteria
* contraindications to study drugs * anticipated change in systemic hypotensive therapy during the trial * use of any corticosteroids by any route in the three months immediately prior to Visit 2
Countries
United States
Outcome results
None listed